Haisco

Haisco Pharmaceutical Group (hereinafter referred to as "Haisco" or "the Company") was established in 2000. It is a diversified and professional pharmaceutical group listed company integrating new drug research and development, production, manufacturing, sales, and other businesses. Haisco's R&D strength ranks among the top in the chemical pharmaceuticals industry. It is the leading enterprise with the most comprehensive product line in the parenteral nutrition sub-sector and also holds an important position in niche markets such as liver disease treatment, depression, and anti-infection. The company has over 4,200 employees, including 49 doctors and 399 masters. Haisco was listed on the Shenzhen Stock Exchange A-share market on January 17, 2012. In 2021, it achieved sales of 2.773 billion RMB and a net profit of 345 million RMB. Haisco boasts strong technical capabilities, with nearly 800 researchers, including many doctors and masters, working at its R&D center. The current research work covers multiple disease areas such as anesthesia and analgesia, diabetes and its complications, oncology, neuropathic pain, parenteral nutrition, cardiovascular and cerebrovascular diseases, digestive system, and respiratory system. Over 90 new projects have been initiated in the specialized fields of innovative drugs and high-end generic drugs. Currently, there are eight Class 1 new drugs under research. The company's independently developed first-in-class intravenous anesthetic drug with independent intellectual property rights in China, Cyclpropofol Injection, has successfully been launched in the market. Cyclpropofol has received approval for new indications including "sedation and anesthesia in non-intubated surgery/procedures," "induction and maintenance of general anesthesia," and "sedation during intensive care." By the end of December 2021, one year after its launch, Cyclpropofol had entered nearly 400 hospitals in China, with sales reaching approximately 60 million RMB. Meanwhile, in the United States, it has been approved by the FDA to bypass Phase I and II clinical trials and proceed directly to Phase III clinical trials, which are currently enrolling participants. The R&D center has independent research buildings for generic and innovative drugs as well as pilot production bases, equipped with advanced precision scientific instruments, and its testing conditions are at a leading level in China. Since its establishment in 2000, the company has successfully developed 70 varieties, including 22 first-to-market generics, with a first-to-market rate exceeding 31%, placing its first-to-market success rate at the forefront of the industry. Additionally, 24 products have passed/been deemed to pass the consistency evaluation. The company has a product portfolio covering multiple niche areas such as anesthesia and analgesia, parenteral nutrition, antiemetic for cancer treatment, liver disease treatment, digestive system, nervous system, and anti-infective. Among the existing 49 varieties, most are domestically first or exclusive generics. Major products include Cyclpropofol Injection, Compound Amino Acid Injection (18AA-VII), Fat Emulsion Amino Acids (17) Glucose (11%) Injection, Dolasetron Mesylate Injection, Methylprednisolone Sodium Succinate for Injection, Flupentixol and Melitracen Tablets, and Polyene Phosphatidylcholine Injection, etc. Haisco has a robust sales network and mature marketing channels. Following the guiding principle of "self-built teams, cooperative operations," the company has built an extensive sales network covering major provinces and cities in China. Guided by the twelve-word policy of "medical-driven, academic-led, sales execution," we adopt a diversified marketing model, innovate through pilot programs, and transition towards refinement, systematization, and platformization. Currently, our company has over 1,000 sales personnel, nearly 5,000 management representatives, and covers approximately 10,000 secondary-level and above hospitals.